Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.39 +3.09%

+$0.08 today

Market cap
$270.48M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.69M

Average 3.81M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$67.53M

FY 2025 · Annual

Investing Cash Flow

-$132.47M

FY 2025 · Annual

Financing Cash Flow

$206.84M

FY 2025 · Annual

+1959.4% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(97.09M)(84.71M)(88.45M)(95.06M)(88.09M)
Depreciation & Amortization551K493K477K238K112K
Deferred Income Tax0000(681K)
Stock-Based Compensation5.52M8.1M10.64M14.39M16.08M
Change in Working Capital(251K)14.11M(8.27M)4.48M6.75M
Accounts Receivables6.53M3.3M(2.31M)1.74M2.06M
Inventory00000
Accounts Payables1.42M2.77M(2.73M)(1.86M)2.51M
Other Working Capital(8.21M)8.04M(3.23M)4.6M2.19M
Other Non-Cash Items13.03M(578K)9.79M(3.9M)(1.7M)
Operating Cash Flow(78.24M)(62.59M)(75.81M)(79.85M)(67.54M)
Capital Expenditures(12.31M)(126K)(47K)0(11K)
Acquisitions (Net)00000
Purchases of Investments(7.59M)(73.27M)(88.63M)(115.73M)(285.45M)
Sales of Investments107.43M0102.41M87.35M152.99M
Other Investing Activities(195K)0000
Investing Cash Flow87.52M(73.4M)13.73M(28.39M)(132.47M)
Debt Repayment000033.92M
Common Stock Issued65.04M56.35M86.6M9.99M173.73M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities58K434K(496K)50K(709K)
Financing Cash Flow65.1M56.78M86.11M10.04M206.84M
Effect of Forex Changes00000
Net Change in Cash74.38M(79.2M)24.03M(98.19M)6.83M
Free Cash Flow(90.55M)(62.71M)(75.86M)(79.85M)(67.55M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$88.1M
+ D&A$112.0K
+ Stock-Based Comp$16.1M
- Deferred Tax-$681.0K
+ Working Capital$6.8M
- Other Non-Cash-$1.7M
= Operating Cash Flow-$67.5M
- Capex-$11.0K
= Free Cash Flow-$67.5M

Analysis

FY2025 free cash flow is -$67.5M. FCF conversion is 76.7% of net income. Operating cash flow was -$67.5M, with capex of -$11.0K. The largest bridge item is Stock-Based Comp at $16.1M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 13, 2026
4Statement of changes in beneficial ownershipNov 13, 2026
4Statement of changes in beneficial ownershipNov 13, 2026
4Statement of changes in beneficial ownershipNov 13, 2026
10-QQuarterly reportNov 12, 2026

Does ALT generate free cash flow?

Altimmune, Inc. (ALT) generated -$67.55M of free cash flow in fiscal 2025.

How much operating cash flow does ALT produce?

Operating cash flow was -$67.53M, before capital expenditures of $11,000.00.